EyePoint Reports Fourth-Quarter and Full-Year 2025 Financial Results, Provides Corporate Update

Published on March 9, 2026
WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and a developer of therapeutics for patients with serious retinal diseases, announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. For the fourth quarter, total net revenue was $0.6 million, a decrease from $11.6 million reported in the same period last year. The full-year 2025 total net revenue was $31.4 million, down from $43.3 million in the corresponding period of 2024.
Continue reading on website
Other news

Prevent Blindness Debuts ‘Best Eyes for Life’ Multimedia Campaign to Raise Awareness for Eye Health and Safety

March 9, 2026
CHICAGO—Prevent Blindness, a nonprofit eye health organization, is rolling out the new “Best Eyes for Life” multimedia educational campaign featuring “Iris and Cornelius,” two characters who engage in everyday eye-related situations to raise awareness and prioritize eye health and safety. The campaign is debuting following a recent Prevent Blindness consumer survey, which revealed nearly 75 percen

The Vision Council’s Latest Provider inSights Research Shows ECPs Adapted to Tariffs, Reported Stronger Second Half of 2025

March 9, 2026
ALEXANDRIA, Va.—The Vision Council has announced the publication of its latest research report, Provider inSights Q3–Q4 2025, which shows that eyecare providers experienced meaningful revenue improvements in the second half of 2025, even as tariffs, inflation and staffing challenges continued to strain day-to-day operations. The report, based on a survey of more than 300 U.S. eyecare professionals